Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China.

Qi YuJohn C StevensonTetiana TatarchukRossella Elena NappiMarcelo Graziano CustodioElke KahlerTommaso SimonciniJunyi YangMulan Ren

Published in: Climacteric : the journal of the International Menopause Society (2024)

Oral, ultra-low-dose continuous combined 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone improved VMS compared with placebo in European and Chinese postmenopausal women, with a positive impact on health-related quality of life.

Keyphrases

low dose
high dose
high resolution
estrogen receptor
bone mineral density
double blind
combination therapy
sleep quality
body composition
postmenopausal women